Edoxaban: An Update on the New Oral Direct Factor Xa Inhibitor

Edoxaban is a once-daily oral anticoagulant that rapidly and selectively inhibits factor Xa in a concentration-dependent manner. This review describes the extensive clinical development program of edoxaban, including phase III studies in patients with non-valvular atrial fibrillation (NVAF) and symp...

Descripción completa

Detalles Bibliográficos
Autores principales: Bounameaux, Henri, Camm, A. John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2014
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4107274/
https://www.ncbi.nlm.nih.gov/pubmed/25034361
http://dx.doi.org/10.1007/s40265-014-0261-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4107274/
https://www.ncbi.nlm.nih.gov/pubmed/25034361
http://dx.doi.org/10.1007/s40265-014-0261-1

Ejemplares similares